Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 3 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $12.1M
- Insider buysLast 90 days, $323.4K in total
- 3
- Insider sellsLast 90 days, $128.3K in total
- 3
- 13F holdersQ2 2026, −1 vs. previous quarter
- 23
- 13F valueReported value at the end of Q2 2026
- $2.31M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $7.70M
- +0.1% year over year
- Net income, FY2025
- -$33.4M
- No comparable prior period
- Free cash flow, FY2025
- -$39.9M
- No comparable prior period
- Revenue, Q2 FY2026
- $5.00K
- −99.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $33.4M (433.7% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 47.4K
- Shares sold short
- Change
- +31.6K
- +200.8% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding BOLT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding BOLT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Bolt Biotherapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2026 (view filing)2:57 PM ET | Nov 9 | 1 day | Coastlands Capital LP10% Owner | PPurchase | +50.0K | $6.38 | +$319.0K | +12.1%462.4K after | |
| Sep 21, 2026 (view filing)6:05 PM ET | Sep 16-18 | 5 daysLate | Yonehiro GrantChief Operating Officer | SSale | −13.2K | $3.32 | −$43.8K | −43.3%17.3K after | 3 lots |
| Sep 21, 2026 (view filing)6:04 PM ET | Jun 5 | 108 daysLate | Nemec SarahSenior VP, Finance and PAO | PPurchase | +509 | $3.88 | +$1.97K | +36.0%1.92K after | |
| Sep 21, 2026 (view filing)6:04 PM ET | Sep 16-18 | 5 daysLate | Nemec SarahSenior VP, Finance and PAO | SSale | −7.84K | $3.32 | −$26.1K | −31.5%17.1K after | 3 lots |
| Sep 21, 2026 (view filing)6:03 PM ET | Jun 5 | 108 daysLate | Quinn William P.President, CEO and CFO | PPurchase | +637 | $3.88 | +$2.47K | +27.5%2.95K after | |
| Sep 21, 2026 (view filing)6:03 PM ET | Sep 16-18 | 5 daysLate | Quinn William P.President, CEO and CFO | SSale | −17.6K | $3.32 | −$58.4K | −40.9%25.4K after | 3 lots |
| Feb 4, 2026 (view filing) | Dec 5, 2025 | 61 daysLate | Quinn William P.President, CEO and CFO | PPurchase | +125 | $4.61 | +$576.25 | +5.7%2.31K after | |
| Feb 4, 2026 (view filing) | Dec 5, 2025 | 61 daysLate | Nemec SarahSenior VP, Finance and PAO | PPurchase | +125 | $4.61 | +$576.25 | +9.7%1.42K after | |
| Oct 24, 2025 (view filing) | Jun 6 | 140 daysLate | Nemec SarahSenior VP, Finance and PAO | PPurchase | +125 | $5.49 | +$686.25 | +15.3%943 after | |
| Oct 24, 2025 (view filing) | Jun 6 | 140 daysLate | Quinn William P.President, CEO and CFO | PPurchase | +125 | $5.49 | +$686.25 | +6.1%2.19K after |
Top 10 13F holders, Q2 2026
See all 23 holdersThe largest institutional positions in Bolt Biotherapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sofinnova Investments, Inc. | 137,721 | $530.2K | 0.03% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 98,625 | $379.7K | 0.00% | +21,400+27.7% | Added |
| Vivo Capital, LLC | 72,414 | $278.8K | 0.03% | 00.0% | Unchanged |
| Citadel Advisors LLC | 56,903 | $219.1K | 0.00% | +46,794+462.9% | Added |
| T3 Companies, LLC | 38,000 | $146.3K | 0.17% | 00.0% | Unchanged |
| Board of Trustees of The Leland Stanford Junior University | 35,977 | $138.5K | 0.03% | 00.0% | Unchanged |
| Pfizer Inc | 31,305 | $133.8K | 0.08% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 30,800 | $118.6K | 0.01% | 00.0% | Unchanged |
| Nano Cap New Millennium Growth Fund L P | 27,500 | $105.9K | 0.08% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 19,119 | $73.6K | 0.00% | −9,672−33.6% | Reduced |
Holders of 5% or more of BOLT
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Bolt Biotherapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Coastlands Capital LP | 13G | 17.50%412.4K shares | New | Nov 6, 20261 filing | Nov 6, 2026 | SEC |
| Tang Capital Management LLC | 13G/A | 9.90%3.81M shares | – | May 15, 20251 filing | May 15, 2025 | SEC |
| Renaissance Technologies LLC | 13G | 5.13%98.6K shares | New | Aug 13, 20261 filing | Aug 13, 2026 | SEC |